Magnetic field and pH synergy controls therapeutic burst


Australian researchers have shown how alternating magnetic fields could be used to localise the release of cancer-fighting drugs to cancer cells, limiting side effects in the rest of the body.

May Lim at the University of New South Wales, and colleagues, have devised a system where a magnetite (Fe3O4) nanoparticle is bound to a temperature-responsive polymer onto which drug molecules can be attached via Schiff base bonds.

Two simultaneous stimuli are necessary for rapid drug deployment – acidic conditions to break the chemical bonds between the polymer and the drug, and an alternating magnetic field to provide sufficient thermal energy to accelerate contraction of the polymer and trigger a therapeutic ‘burst’. As cancer cells are typically more acidic than healthy tissue, this innovative approach could enable drug release precisely when and where it is required, minimising damage to healthy cells.

A magnetic field combined with the acidic environment of cancer tissue results in rapid hydrolysis of the Schiff base bond

‘We envisage the nanoparticle–polymer composite will be injected into the affected tissue; this is how magnetic nanoparticle-based therapy is currently being administered,’ Lim tells Chemistry World.

‘Nanomedicine could be the key to deal with cancer as it is focused on targeted, personalised treatment,’ says to Cordelia Selomulya, a functional materials expert at Monash University in Australia. But could materials like this work in the body? ‘Here, the main component is magnetite which is FDA [the US Food and Drug Administration]-approved. If the composites can be shown to be non-toxic to healthy cells in vivo, then they could be adopted for medical applications. Of course the translation into medicinal applications, especially in humans, has strict requirements’.

Although the research is still at the proof-of-concept stage, the team are hopeful. Polymers similar to the one employed by the group have been shown to be safe and non-toxic, and are currently undergoing clinical trials. The group’s next task will be to decrease the size of the nanoparticles, whilst remaining responsive to magnetic field strengths and frequencies that are clinically relevant.

References

This paper is free to access until 2 May 2014. Download it here:

A Dunn et al, Polym. Chem., 2014, DOI: 10.1039/c4py00150h


Related Content

Stealthy nanoparticles gather to take on tumours

9 July 2013 Research

news image

Zwitterion coated gold nanoparticles that accumulate in cancer cells could deliver drugs to tumours while leaving healthy tis...

Breaking through the barrier

31 May 2011 Feature

news image

Getting drug molecules into the brain means crossing the defensive blood-brain barrier. Anthony King investigates how chemist...

Most Read

UC Davis chemist sentenced to four years over explosion

19 November 2014 News and Analysis

news image

Postdoc sentenced over attempt to make explosive device and reckless disposal of hazardous waste

Grad student blamed for research misconduct at Utah

13 November 2014 News and Analysis

news image

Two papers have been retracted due to image falsification at the University of Utah

Most Commented

Beetle behind breath test for bank notes

17 November 2014 Research

news image

Photonic crystal inks inspired by longhorn beetle could help to fight counterfeiting

Bayer wins race to buy Merck & Co consumer care

9 May 2014 Business

news image

$14bn deal will make Aspirin inventor the number two over-the-counter healthcare company